Wright, P. E. & Dyson, H. J. Intrinsically unstructured proteins: Re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321–331 (1999).
Google Scholar
Dunker, A. K. et al. Intrinsically disordered protein. J. Mol. Graph. Model. 19, 26–59 (2001).
Google Scholar
Dyson, H. J. & Wright, P. E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell. Biol. 6, 197–208 (2005).
Google Scholar
Wright, P. E. & Dyson, H. J. Intrinsically disordered proteins in cellular signalling and regulation. Nat. Rev. Mol. Cell. Biol. 16, 18–29 (2015).
Google Scholar
Uversky, V. N., Oldfield, C. J. & Dunker, A. K. Intrinsically disordered proteins in human diseases: Introducing the D2 concept. Annu. Rev. Biophys. 37, 215–246 (2008).
Google Scholar
Greig, K. T., Carotta, S. & Nutt, S. L. Critical roles for c-Myb in hematopoietic progenitor cells. Semin. Immunol. 20, 247–256 (2008).
Google Scholar
Ramsay, R. G. & Gonda, T. J. MYB function in normal and cancer cells. Nat. Rev. Cancer 8, 523–534 (2008).
Google Scholar
Wang, X., Angelis, N. & Thein, S. L. MYB: A regulatory factor in hematopoiesis. Gene 665, 6–17 (2018).
Google Scholar
Oh, I. H. & Reddy, E. P. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18, 3017–3033 (1999).
Google Scholar
Biroccio, A. et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: Clinical and experimental findings. Am. J. Pathol. 158, 1289–1299 (2001).
Google Scholar
Drabsch, Y. et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc. Natl. Acad. Sci. USA 104, 13762–13767 (2007).
Google Scholar
Miao, R. Y. et al. MYB is essential for mammary tumorigenesis. Cancer Res. 71, 7029–7037 (2011).
Google Scholar
Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628–1640 (2011).
Google Scholar
Pattabiraman, D. R. & Gonda, T. J. Role and potential for therapeutic targeting of MYB in leukemia. Leukemia 27, 269–277 (2013).
Google Scholar
Liu, X., Gold, K. A. & Dmitrovsky, E. The Myb-p300 interaction is a novel molecular pharmacologic target. Mol. Cancer Ther. 14, 1273–1275 (2015).
Google Scholar
Mitra, P. Transcription regulation of MYB: A potential and novel therapeutic target in cancer. Ann. Transl. Med. 6, 443 (2018).
Google Scholar
Ciciro, Y. & Sala, A. MYB oncoproteins: Emerging players and potential therapeutic targets in human cancer. Oncogenesis 10, 19 (2021).
Google Scholar
Best, J. L. et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc. Natl. Acad. Sci. USA 101, 17622–17627 (2004).
Google Scholar
Li, B. X. & Xiao, X. Discovery of a small-molecule inhibitor of the KIX-KID interaction. ChemBioChem 10, 2721–2724 (2009).
Google Scholar
Uttarkar, S. et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood 127, 1173–1182 (2016).
Google Scholar
Lu, H. et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct. Target. Ther. 5, 213. https://doi.org/10.1038/s41392-020-00315-3 (2020).
Google Scholar
Tsomaia, N. Peptide therapeutics: Targeting the undruggable space. Eur. J. Med. Chem. 94, 459–470 (2015).
Google Scholar
Lee, A. C., Harris, J. L., Khanna, K. K. & Hong, J. H. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci. 20, 2383. https://doi.org/10.3390/ijms20102383 (2019).
Google Scholar
Sakura, H. et al. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc. Natl. Acad. Sci. USA 86, 5758–5762 (1989).
Google Scholar
Ogata, K. et al. Solution structure of a DNA-binding unit of Myb: A helix-turn-helix-related motif with conserved tryptophans forming a hydrophobic core. Proc. Natl. Acad. Sci. USA 89, 6428–6432 (1992).
Google Scholar
Aziz, N. et al. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc. Natl. Acad. Sci. USA 92, 6429–6433 (1995).
Google Scholar
Bies, J. & Wolff, L. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene 14, 203–212 (1997).
Google Scholar
Bies, J., Markus, J. & Wolff, L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J. Biol. Chem. 277, 8999–9009 (2002).
Google Scholar
Radhakrishnan, I. et al. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator:coactivator interactions. Cell 91, 741–752 (1997).
Google Scholar
Zor, T., De Guzman, R. N., Dyson, H. J. & Wright, P. E. Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. J. Mol. Biol. 337, 521–534 (2004).
Google Scholar
Lee, C. W., Arai, M., Martinez-Yamout, M. A., Dyson, H. J. & Wright, P. E. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry 48, 2115–2124 (2009).
Google Scholar
Van Orden, K., Giebler, H. A., Lemasson, I., Gonzales, M. & Nyborg, J. K. Binding of p53 to the KIX domain of CREB binding protein: A potential link to human T-cell leukemia virus, type I-associated leukemogenesis. J. Biol. Chem. 274, 26321–26328 (1999).
Google Scholar
Campbell, K. M. & Lumb, K. J. Structurally distinct modes of recognition of the KIX domain of CBP by Jun and CREB. Biochemistry 41, 13956–13964 (2002).
Google Scholar
Vendel, A. C. & Lumb, K. J. Molecular recognition of the human coactivator CBP by the HIV-1 transcriptional activator Tat. Biochemistry 42, 910–916 (2003).
Google Scholar
De Guzman, R. N., Goto, N. K., Dyson, H. J. & Wright, P. E. Structural basis for cooperative transcription factor binding to the CBP coactivator. J. Mol. Biol. 355, 1005–1013 (2006).
Google Scholar
Yang, K. et al. Structural basis for cooperative regulation of KIX-mediated transcription pathways by the HTLV-1 HBZ activation domain. Proc. Natl. Acad. Sci. USA 115, 10040–10045 (2018).
Google Scholar
Zor, T., Mayr, B. M., Dyson, H. J., Montminy, M. R. & Wright, P. E. Roles of phosphorylation and helix propensity in the binding of the KIX domain of CREB-binding protein by constitutive (c-Myb) and inducible (CREB) activators. J. Biol. Chem. 277, 42241–42248 (2002).
Google Scholar
Arai, M., Sugase, K., Dyson, H. J. & Wright, P. E. Conformational propensities of intrinsically disordered proteins influence the mechanism of binding and folding. Proc. Natl. Acad. Sci. USA 112, 9614–9619 (2015).
Google Scholar
Poosapati, A., Gregory, E., Borcherds, W. M., Chemes, L. B. & Daughdrill, G. W. Uncoupling the folding and binding of an intrinsically disordered protein. J. Mol. Biol. 430, 2389–2402 (2018).
Google Scholar
Arai, M. Unified understanding of folding and binding mechanisms of globular and intrinsically disordered proteins. Biophys. Rev. 10, 163–181 (2018).
Google Scholar
Muñoz, V. & Serrano, L. Elucidating the folding problem of helical peptides using empirical parameters. Nat. Struct. Biol. 1, 399–409 (1994).
Google Scholar
Muñoz, V. & Serrano, L. Elucidating the folding problem of helical peptides using empirical parameters II. Helix macrodipole effects and rational modification of the helical content of natural peptides. J. Mol. Biol. 245, 275–296 (1995).
Google Scholar
Lacroix, E., Viguera, A. R. & Serrano, L. Elucidating the folding problem of α-helices: Local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. J. Mol. Biol. 284, 173–191 (1998).
Google Scholar
Petukhov, M. et al. Design of stable α-helices using global sequence optimization. J. Pept. Sci. 15, 359–365 (2009).
Google Scholar
Garcia-Aranda, M. I. et al. Helical peptides from VEGF and Vammin hotspots for modulating the VEGF-VEGFR interaction. Org. Biomol. Chem. 11, 1896–1905 (2013).
Google Scholar
Bonache, M. A. et al. De novo designed library of linear helical peptides: An exploratory tool in the discovery of protein-protein interaction modulators. ACS Comb. Sci. 16, 250–258 (2014).
Google Scholar
Karoyan, P. et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 4, 197. https://doi.org/10.1038/s42003-021-01736-8 (2021).
Google Scholar
Parker, D. et al. Role of secondary structure in discrimination between constitutive and inducible activators. Mol. Cell. Biol. 19, 5601–5607 (1999).
Google Scholar
Langlois, C. et al. Structure-based design of a potent artificial transactivation domain based on p53. J. Am. Chem. Soc. 134, 1715–1723 (2012).
Google Scholar
Borcherds, W. et al. Disorder and residual helicity alter p53-Mdm2 binding affinity and signaling in cells. Nat. Chem. Biol. 10, 1000–1002 (2014).
Google Scholar
Iešmantavičius, V., Dogan, J., Jemth, P., Teilum, K. & Kjaergaard, M. Helical propensity in an intrinsically disordered protein accelerates ligand binding. Angew. Chem. Int. Ed. Engl. 53, 1548–1551 (2014).
Google Scholar
Crabtree, M. D. et al. Conserved helix-flanking prolines modulate intrinsically disordered protein: Target affinity by altering the lifetime of the bound complex. Biochemistry 56, 2379–2384 (2017).
Google Scholar
Dahal, L., Kwan, T. O. C., Hollins, J. J. & Clarke, J. Promiscuous and selective: How intrinsically disordered BH3 proteins interact with their pro-survival partner MCL-1. J. Mol. Biol. 430, 2468–2477 (2018).
Google Scholar
Tompa, P. & Fuxreiter, M. Fuzzy complexes: Polymorphism and structural disorder in protein-protein interactions. Trends Biochem. Sci. 33, 2–8 (2008).
Google Scholar
Wolny, M. et al. Characterization of long and stable de novo single alpha-helix domains provides novel insight into their stability. Sci. Rep. 7, 44341. https://doi.org/10.1038/srep44341 (2017).
Google Scholar
Mohan, A. et al. Analysis of molecular recognition features (MoRFs). J. Mol. Biol. 362, 1043–1059 (2006).
Google Scholar
Guharoy, M. & Chakrabarti, P. Secondary structure based analysis and classification of biological interfaces: Identification of binding motifs in protein-protein interactions. Bioinformatics 23, 1909–1918 (2007).
Google Scholar
Jochim, A. L. & Arora, P. S. Assessment of helical interfaces in protein-protein interactions. Mol. Biosyst. 5, 924–926 (2009).
Google Scholar
Klein, M. A. Stabilized helical peptides: A strategy to target protein-protein interactions. ACS Med. Chem. Lett. 5, 838–839 (2014).
Google Scholar
Klein, M. Stabilized helical peptides: Overview of the technologies and its impact on drug discovery. Expert Opin. Drug Discov. 12, 1117–1125 (2017).
Google Scholar
Ramaswamy, K. et al. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat. Commun. 9, 110. https://doi.org/10.1038/s41467-017-02618-6 (2018).
Google Scholar
Wang, F. et al. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control. Release 174, 126–136 (2014).
Google Scholar
Yang, N. J. & Hinner, M. J. Getting across the cell membrane: An overview for small molecules, peptides, and proteins. Methods Mol. Biol. 1266, 29–53 (2015).
Google Scholar
Matsson, P. & Kihlberg, J. How big is too big for cell permeability?. J. Med. Chem. 60, 1662–1664 (2017).
Google Scholar
Fraczkiewicz, R. & Braun, W. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J. Comput. Chem. 19, 319–333 (1998).
Google Scholar
Hoover, D. M. & Lubkowski, J. DNAWorks: An automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res. 30, e43 (2002).
Google Scholar
Chen, Y. H., Yang, J. T. & Martinez, H. M. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11, 4120–4131 (1972).
Google Scholar
